Conversion of the anti-tumor agent tasidotin (ILX651) to its active metabolite by prolyl oligopeptidase

Charles E. Deutch, Roy Krumbholz, Steve M. Schmid, Peter L. Bonate, Peter Jurutka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Tasidotin (ILX651) is a dolastatin analog active against several solid tumors. It is converted in vivo into two metabolites: M1, which lacks the carboxyl-terminal tert-butylamide group and is more active pharmacologically, and M2, which lacks this group and an adjacent proline residue. Both tasidotin and metabolite M1 were found to be competitive inhibitors of highly purified prolyl oligopeptidase (POP; EC 3.4.21.26) from Flavobacterium meningosepticum as measured by chromogenic and fluorogenic assays. HPLC analysis showed that POP converted tasidotin to M1 but not further to M2. Formation of M1 was linear for 120 min with a Vmax of 9.26 ng/mL min and an apparent Km of 0.238 mM (153 μg/mL). Several other enzymes known to cleave peptides at proline residues did not convert tasidotin to either M1 or M2. These results suggest that in addition to its known roles in the metabolism of physiologically active peptides and glutens, POP may function in drug metabolism and the level of POP activity in human tumor cells may determine their susceptibility to the pharmacologically active form of this drug.

Original languageEnglish (US)
Pages (from-to)246-251
Number of pages6
JournalEnzyme and Microbial Technology
Volume46
Issue number3-4
DOIs
StatePublished - Mar 5 2010
Externally publishedYes

Fingerprint

prolyl oligopeptidase
Metabolites
Metabolism
Peptides
Tumors
Chromogenics
Assays
Neoplasms
Proline
Enzymes
Cells
Chryseobacterium
Glutens
Human Activities
Pharmaceutical Preparations
High Pressure Liquid Chromatography
tasidotin

Keywords

  • ILX651
  • Microtubule inhibitor
  • Prolyl endopeptidase
  • Prolyl oligopeptidase
  • Solid tumors
  • Tasidotin

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Applied Microbiology and Biotechnology

Cite this

Conversion of the anti-tumor agent tasidotin (ILX651) to its active metabolite by prolyl oligopeptidase. / Deutch, Charles E.; Krumbholz, Roy; Schmid, Steve M.; Bonate, Peter L.; Jurutka, Peter.

In: Enzyme and Microbial Technology, Vol. 46, No. 3-4, 05.03.2010, p. 246-251.

Research output: Contribution to journalArticle

Deutch, Charles E. ; Krumbholz, Roy ; Schmid, Steve M. ; Bonate, Peter L. ; Jurutka, Peter. / Conversion of the anti-tumor agent tasidotin (ILX651) to its active metabolite by prolyl oligopeptidase. In: Enzyme and Microbial Technology. 2010 ; Vol. 46, No. 3-4. pp. 246-251.
@article{175845d84825494b9d0444cd596b7cc7,
title = "Conversion of the anti-tumor agent tasidotin (ILX651) to its active metabolite by prolyl oligopeptidase",
abstract = "Tasidotin (ILX651) is a dolastatin analog active against several solid tumors. It is converted in vivo into two metabolites: M1, which lacks the carboxyl-terminal tert-butylamide group and is more active pharmacologically, and M2, which lacks this group and an adjacent proline residue. Both tasidotin and metabolite M1 were found to be competitive inhibitors of highly purified prolyl oligopeptidase (POP; EC 3.4.21.26) from Flavobacterium meningosepticum as measured by chromogenic and fluorogenic assays. HPLC analysis showed that POP converted tasidotin to M1 but not further to M2. Formation of M1 was linear for 120 min with a Vmax of 9.26 ng/mL min and an apparent Km of 0.238 mM (153 μg/mL). Several other enzymes known to cleave peptides at proline residues did not convert tasidotin to either M1 or M2. These results suggest that in addition to its known roles in the metabolism of physiologically active peptides and glutens, POP may function in drug metabolism and the level of POP activity in human tumor cells may determine their susceptibility to the pharmacologically active form of this drug.",
keywords = "ILX651, Microtubule inhibitor, Prolyl endopeptidase, Prolyl oligopeptidase, Solid tumors, Tasidotin",
author = "Deutch, {Charles E.} and Roy Krumbholz and Schmid, {Steve M.} and Bonate, {Peter L.} and Peter Jurutka",
year = "2010",
month = "3",
day = "5",
doi = "10.1016/j.enzmictec.2009.10.013",
language = "English (US)",
volume = "46",
pages = "246--251",
journal = "Enzyme and Microbial Technology",
issn = "0141-0229",
publisher = "Elsevier Inc.",
number = "3-4",

}

TY - JOUR

T1 - Conversion of the anti-tumor agent tasidotin (ILX651) to its active metabolite by prolyl oligopeptidase

AU - Deutch, Charles E.

AU - Krumbholz, Roy

AU - Schmid, Steve M.

AU - Bonate, Peter L.

AU - Jurutka, Peter

PY - 2010/3/5

Y1 - 2010/3/5

N2 - Tasidotin (ILX651) is a dolastatin analog active against several solid tumors. It is converted in vivo into two metabolites: M1, which lacks the carboxyl-terminal tert-butylamide group and is more active pharmacologically, and M2, which lacks this group and an adjacent proline residue. Both tasidotin and metabolite M1 were found to be competitive inhibitors of highly purified prolyl oligopeptidase (POP; EC 3.4.21.26) from Flavobacterium meningosepticum as measured by chromogenic and fluorogenic assays. HPLC analysis showed that POP converted tasidotin to M1 but not further to M2. Formation of M1 was linear for 120 min with a Vmax of 9.26 ng/mL min and an apparent Km of 0.238 mM (153 μg/mL). Several other enzymes known to cleave peptides at proline residues did not convert tasidotin to either M1 or M2. These results suggest that in addition to its known roles in the metabolism of physiologically active peptides and glutens, POP may function in drug metabolism and the level of POP activity in human tumor cells may determine their susceptibility to the pharmacologically active form of this drug.

AB - Tasidotin (ILX651) is a dolastatin analog active against several solid tumors. It is converted in vivo into two metabolites: M1, which lacks the carboxyl-terminal tert-butylamide group and is more active pharmacologically, and M2, which lacks this group and an adjacent proline residue. Both tasidotin and metabolite M1 were found to be competitive inhibitors of highly purified prolyl oligopeptidase (POP; EC 3.4.21.26) from Flavobacterium meningosepticum as measured by chromogenic and fluorogenic assays. HPLC analysis showed that POP converted tasidotin to M1 but not further to M2. Formation of M1 was linear for 120 min with a Vmax of 9.26 ng/mL min and an apparent Km of 0.238 mM (153 μg/mL). Several other enzymes known to cleave peptides at proline residues did not convert tasidotin to either M1 or M2. These results suggest that in addition to its known roles in the metabolism of physiologically active peptides and glutens, POP may function in drug metabolism and the level of POP activity in human tumor cells may determine their susceptibility to the pharmacologically active form of this drug.

KW - ILX651

KW - Microtubule inhibitor

KW - Prolyl endopeptidase

KW - Prolyl oligopeptidase

KW - Solid tumors

KW - Tasidotin

UR - http://www.scopus.com/inward/record.url?scp=74249124113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74249124113&partnerID=8YFLogxK

U2 - 10.1016/j.enzmictec.2009.10.013

DO - 10.1016/j.enzmictec.2009.10.013

M3 - Article

AN - SCOPUS:74249124113

VL - 46

SP - 246

EP - 251

JO - Enzyme and Microbial Technology

JF - Enzyme and Microbial Technology

SN - 0141-0229

IS - 3-4

ER -